Russia's war in Ukraine is now delaying data readouts, as Tricida says its second-chance trial needs more time
A small cap biotech reported Wednesday that the Russian invasion of Ukraine will delay the interim analysis for a large study, suggesting the war could bring new challenges to the industry.
Tricida said Wednesday afternoon it will have to delay the data readout for its experimental CKD drug veverimer by at least one quarter, from the third quarter of this year to the fourth quarter. About 15% of patients enrolled in the 1,600-person study are from Ukraine, the company said, leading to what the biotech calls “anticipated disruption and/or delays” in collecting the data.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.